Millennium Capital Advisors LLC Makes New $3.94 Million Investment in Eli Lilly and Company $LLY

Millennium Capital Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, Holdings Channel reports. The institutional investor bought 3,666 shares of the company’s stock, valued at approximately $3,940,000. Eli Lilly and Company comprises approximately 2.3% of Millennium Capital Advisors LLC’s investment portfolio, making the stock its 9th biggest position.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. increased its position in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $749,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,005.20 on Friday. The firm has a 50 day moving average of $939.88 and a 200 day moving average of $997.00. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $946.63 billion, a price-to-earnings ratio of 35.71, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LLY. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, May 4th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Finally, CICC Research lifted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,218.33.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for Eli Lilly, lifting its forecast to $36.30 per share from $36.06 and above the broader consensus of $35.80, signaling continued earnings momentum.
• Positive Sentiment: Guggenheim recently boosted Lilly’s price target by $52 after the company’s strong first-quarter results, reinforcing the view that analysts see more upside after another blowout quarter.
• Positive Sentiment: Media coverage continues to highlight Lilly as one of the most watched stocks, with commentary pointing to its dominant position in the weight-loss drug market and ongoing bullish investor interest. Article: Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: Several reports pointed to Lilly’s expanding pipeline, including new and advancing trials in ALS, GI disease, and immuno-dermatology, which adds optionality beyond its core diabetes and obesity franchises.
• Positive Sentiment: Investor sentiment also got a boost from headlines calling Lilly a potential bull-market leader and suggesting the stock could approach $1,100 if momentum continues. Article: Is Eli Lilly Going To $1,100?
• Neutral Sentiment: Lilly and UNICEF announced a $50 million partnership tied to the company’s 150th anniversary, which may help its ESG profile and public image, but the direct earnings impact appears limited in the near term.
• Neutral Sentiment: Some articles were mainly awareness pieces or broad market commentary rather than company-specific catalysts, so they are unlikely to be major stock drivers on their own.
• Negative Sentiment: Broader market commentary warned that the S&P 500 may be due for a correction, which could create short-term pressure on high-multiple growth stocks like Lilly if risk appetite fades.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.